Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update

Stock Information for Alector Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Alector Inc.

Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer
Alector to Participate in the Bank of America CNS Therapeutics Conference
ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm
ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm
ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm
Alector Reports Third Quarter 2025 Financial Results and Provides Business Update
ATTENTION Alector, Inc. (ALEC) Investors: Possible Fraud - Contact Levi & Korsinsky Today
Lost Money on Alector, Inc. (ALEC)? Contact Levi & Korsinsky About Investigation

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.